142 related articles for article (PubMed ID: 38716804)
1. Evaluating the utility of
Nakasone ES; Zemla TJ; Yu M; Lin SY; Ou FS; Carter K; Innocenti F; Saltz L; Grady WM; Cohen SA
Epigenetics; 2024 Dec; 19(1):2349980. PubMed ID: 38716804
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).
Symonds L; Yu M; Zhang Y; Ou FS; Zemla TJ; Carter K; Bertagnolli M; Innocenti F; Bosch LJ; Meijer GA; Carvalho B; Grady WM; Cohen SA
Epigenetics; 2022 Dec; 17(12):1715-1725. PubMed ID: 35412430
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
4. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.
Wang Y; He T; Herman JG; Linghu E; Yang Y; Fuks F; Zhou F; Song L; Guo M
Clin Epigenetics; 2017; 9():115. PubMed ID: 29075358
[TBL] [Abstract][Full Text] [Related]
5. Re-assessing
Vedeld HM; Nesbakken A; Lothe RA; Lind GE
Clin Epigenetics; 2018; 10():70. PubMed ID: 29854011
[TBL] [Abstract][Full Text] [Related]
6. Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer.
Nie C; Han X; Wei R; Leonteva A; Hong J; Du X; Wang J; Zhu L; Zhao Y; Xue Y; Zhou H; Tian W
BMC Cancer; 2021 May; 21(1):551. PubMed ID: 33992091
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
8. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers.
Vedeld HM; Andresen K; Eilertsen IA; Nesbakken A; Seruca R; Gladhaug IP; Thiis-Evensen E; Rognum TO; Boberg KM; Lind GE
Int J Cancer; 2015 Feb; 136(4):844-53. PubMed ID: 24948044
[TBL] [Abstract][Full Text] [Related]
9. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
10. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy.
Yokoi K; Harada H; Yokota K; Ishii S; Tanaka T; Nishizawa N; Shimazu M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
Ann Surg Oncol; 2019 Feb; 26(2):406-414. PubMed ID: 30311169
[TBL] [Abstract][Full Text] [Related]
12. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.
Draht MX; Smits KM; Tournier B; Jooste V; Chapusot C; Carvalho B; Cleven AH; Derks S; Wouters KA; Belt EJ; Stockmann HB; Bril H; Weijenberg MP; van den Brandt PA; de Bruïne AP; Herman JG; Meijer GA; Piard F; Melotte V; van Engeland M
Mol Oncol; 2014 May; 8(3):679-88. PubMed ID: 24560444
[TBL] [Abstract][Full Text] [Related]
13. NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy.
Chang SY; Kuo CC; Wu CC; Hsiao CW; Hu JM; Hsu CH; Chou YC; Shih YL; Lin YW
Genes Chromosomes Cancer; 2018 May; 57(5):268-277. PubMed ID: 29363224
[TBL] [Abstract][Full Text] [Related]
14. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
[TBL] [Abstract][Full Text] [Related]
15. SOX9 expression predicts relapse of stage II colon cancer patients.
Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
[TBL] [Abstract][Full Text] [Related]
16. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
Chen D; Wen X; Song YS; Rhee YY; Lee TH; Cho NY; Han SW; Kim TY; Kang GH
Clin Epigenetics; 2016; 8():36. PubMed ID: 27051466
[TBL] [Abstract][Full Text] [Related]
17. Genomic and epigenomic integration identifies a prognostic signature in colon cancer.
Yi JM; Dhir M; Van Neste L; Downing SR; Jeschke J; Glöckner SC; de Freitas Calmon M; Hooker CM; Funes JM; Boshoff C; Smits KM; van Engeland M; Weijenberg MP; Iacobuzio-Donahue CA; Herman JG; Schuebel KE; Baylin SB; Ahuja N
Clin Cancer Res; 2011 Mar; 17(6):1535-45. PubMed ID: 21278247
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
[TBL] [Abstract][Full Text] [Related]
19. O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.
Alizadeh Naini M; Kavousipour S; Hasanzarini M; Nasrollah A; Monabati A; Mokarram P
Asian Pac J Cancer Prev; 2018 May; 19(5):1223-1227. PubMed ID: 29801405
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
